摘要翻译：
人类基因组的草图序列大约在十年前就可以获得，但编码的蛋白质组还没有得到最充分的探索。我们对几个大的蛋白质家族的文献计量分析，包括那些已知的“可药物化”的蛋白质家族，揭示出，即使在今天，大多数论文关注的是2000年以前已知的蛋白质。很明显，生物医学研究系统的一个或多个方面严重限制了对蛋白质组“暗物质”中蛋白质的探索，尽管不偏不倚的遗传学方法已经指出了它们的功能相关性。这也许并不奇怪，相对较少的基因组衍生靶点导致了批准的药物。
---
英文标题：
《The human genome and drug discovery after a decade. Roads (still) not
  taken》
---
作者：
Ruth Isserlin, Gary D. Bader, Aled Edwards, Stephen Frye, Timothy
  Willson, Frank H. Yu
---
最新提交年份：
2011
---
分类信息：

一级分类：Quantitative Biology        数量生物学
二级分类：Other Quantitative Biology        其他定量生物学
分类描述：Work in quantitative biology that does not fit into the other q-bio classifications
不适合其他q-bio分类的定量生物学工作
--
一级分类：Quantitative Biology        数量生物学
二级分类：Genomics        基因组学
分类描述：DNA sequencing and assembly; gene and motif finding; RNA editing and alternative splicing; genomic structure and processes (replication, transcription, methylation, etc); mutational processes.
DNA测序与组装；基因和基序的发现；RNA编辑和选择性剪接；基因组结构和过程（复制、转录、甲基化等）；突变过程。
--

---
英文摘要：
  The draft sequence of the human genome became available almost a decade ago but the encoded proteome is not being explored to its fullest. Our bibliometric analysis of several large protein families, including those known to be "druggable", reveals that, even today, most papers focus on proteins that were known prior to 2000. It is evident that one or more aspects of the biomedical research system severely limits the exploration of the proteins in the 'dark matter' of the proteome, despite unbiased genetic approaches that have pointed to their functional relevance. It is perhaps not surprising that relatively few genome-derived targets have led to approved drugs.
---
PDF链接：
https://arxiv.org/pdf/1102.0448